Mary McGann, PharmD
Although most people who are prescribed chimeric antigen receptor (CAR) T-cell therapy receive it entirely as inpatients, there is growing interest in delivering at least part of the revolutionary treatment in the outpatient setting.
Several benefits have boosted interest in outpatient CAR T-cell therapy, including patient preference, shorter hospital lengths of stay and freeing up hospital beds for other interventions, according to Mary McGann, PharmD, BCOP, a